StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Zepbound (tirzepatide by Quarter

Zepbound (tirzepatide — Obesity & obstructive sleep apnea) — Worldwide revenue ($M) ($M)

QuarterlyAnnual

Eli Lilly Zepbound (tirzepatide: $4,928M in Q2 2026, up 45.8% from a year earlier. That is the highest of the 14 quarters on record here.

Latest, Q2 2026
4,928
Period ended Jun 30, 2026
Change on a year earlier
+45.8%
3,381 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
11
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-05) ↗

Reported in Form 10-Q / 10-K Note 2, MD&A & Form 8-K Earnings Releases.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZepbound (tirzepatide — Obesity & obstructive sleep apnea) — Worldwide revenue ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20264,928+45.8%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 20264,160+79.9%Form 10-Q (filed 2026-04-30) ↗
Q4 2025Dec 31, 20254,261+123.4%Earnings Release (Form 8-K FY2025Q4 EX-99.1) (filed 2026-02-04) ↗
Q3 2025Sep 30, 20253,588+185.3%Form 10-Q (filed 2025-10-30) ↗
Q2 2025Jun 30, 20253,381+172.0%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 20252,312+346.8%Form 10-Q (filed 2026-04-30) ↗
Q4 2024Dec 31, 20241,907+984.9%Earnings Release (Form 8-K FY2024Q4 EX-99.1) (filed 2025-02-06) ↗
Q3 2024Sep 30, 20241,258–Form 10-Q (filed 2025-10-30) ↗
Q2 2024Jun 30, 20241,243–Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 2024517–Form 10-Q (filed 2025-05-01) ↗
Q4 2023Dec 31, 2023176–Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
Q3 2023Sep 30, 20230–Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 20230–Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 20230–Form 10-Q (filed 2024-04-30) ↗

Breakdown

What makes up zepbound (tirzepatide

Cite this data

StockData. (2026). Eli Lilly Zepbound (tirzepatide ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-zepbound-ww

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.